Nobel laureate and University of Colorado Cancer Center investigator, Thomas Cech, PhD, uses CRISPR gene editing technology and live cell, single molecule microscopy to watch in real-time, for the first time, the essential interaction between telomerase and telomeres.
University of Colorado Cancer Center study details the hospital procedures that lead to discrepancies between initial, intraoperative pathology evaluation and the results of the final, less pressured examination.
By recognizing a drug's ability to stop cancer's energy overuse, doctors may be able to determine a patient's response to a new, targeted therapy far earlier and with far more precision than watching and waiting for a tumor to shrink.
Text-mining tool developed at CU Cancer Center and published today in Bioinformatics helps researchers map connections between genes, proteins, drugs, diseases.
A University of Colorado Cancer Center study finds that three years post bone marrow transplant, the incidence of severe chronic graft-versus-host disease was 44 percent in patients who had received transplants from matched, unrelated donors (MUD) and 8 percent in patients who had received umbilical cord blood transplants (CBT).
University of Colorado Cancer Center study in Cell Reports shows role of TIP60 in allowing human colorectal cancer cells to survive at the oxygen-poor centers of tumors.
University of Colorado Cancer Center study published online in Oncogene describes mutational landscape of bladder cancer cell lines, demonstrates that alterations in these cells lines do indeed match changes in samples of human bladder cancer and shows genes and gene pathways that may be functionally involved in the ability of bladder cancer to resist therapy.
Hispanic white and non-Hispanic black cancer patients between ages 15 and 29 may be more likely than same-aged white patients to die of their disease, according to a University of Colorado Cancer Center study presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2016.
CU Cancer Center presented at ASCO 2016 finds that in Colorado patients over 50, the rate of CRC is falling at 2.5 percent per year while the rate of CRC in patients under 50 is rising at 0.8 percent per year. The increase in incidence appeared to be driven mostly by an increase in late-stage CRC in the under-50 population with an increase of 2.4 percent per year from 2003 through 2013.
At ASCO 2016: University of Colorado Cancer Center study shows that younger colorectal cancer patients are more likely to have alterations in genes involved in what is known as the Wnt signaling pathway, a system of communication that drives the growth, survival and proliferation of cancer stem cells.
Paul Bunn, Jr., MD, FASCO, distinguished professor at the University of Colorado Cancer Center and James Dudley Professor of Lung Cancer Research at the University of Colorado School of Medicine has been named the 2016 David A. Karnofsky Memorial Award and Lecture recipient, a prestigious award presented at the American Society of Clinical Oncology’s (ASCO) Annual Meeting.
A University of Colorado Cancer Center study shows that more than half of elderly metastatic colorectal cancer patients are receiving three or more treatments, increasing cost and side effects with only one-month gain in median survival.
Even in the healthcare landscape as it existed before the ACA, cancer survivors in states without expanded Medicaid were less likely to have a personal doctor and more likely to report inability to see a doctor due to cost (odds ratios 0.76 and 1.14 respectively).
University of Colorado Cancer Center study shows that some uninsured and low-income breast cancer patients do without even low-cost, high-benefit drugs.
A University of Colorado Cancer Center study recently published in the International Journal of Gynecological Cancer shows that protein cytokeratin 5 (CK5), known to be a marker of poor prognosis in breast cancer, also marks ovarian cancers likely to be resistant to the common chemotherapy cisplatin.
University of Colorado Cancer Center study shows how iron nanoparticles evade human immune system, potentially helping useful particles avoid elimination.
New ACS breast cancer screening guidelines consider anxiety associated with mammography when deciding who should be screened. A University of Colorado Cancer Center study describes a successful intervention to decrease this anxiety, lessening this barrier to screening.
The New England Journal of Medicine reports the results of a 2,259-person study conducted at 11 academic medical centers, including University of Colorado Cancer Center, showing that taking vitamin D and/or calcium supplements after the removal of pre-cancerous colorectal polyps does not reduce risk of developing polyps in the future.
A University of Colorado Cancer Center study being presented at the 16th World Conference on Lung Cancer reveals the full extent to which the CNS may be under-explored in clinical research.
A University of Colorado Cancer Center study being presented today at the 16th World Conference on Lung Cancer in Denver, Colorado sheds light on the best method to determine the threshold at which MET amplification becomes clinically relevant.
Multi-institutional, multidisciplinary study looks past antibiotics and sanitation to a third strategy to control infectious disease: Adjusting the landscape of the human body to remove the mechanism that allows pathogens to cause disease.
Dr. Nicole Ehrhart will be appointed to the Ross M. Wilkins, M.D. Limb Preservation University Chair in Musculoskeletal Biology and Oncology at Colorado State University.
Article in journal Bioinformatics from University of Colorado Cancer Center describes a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best “kinase inhibitor” to silence these dangerous genetic causes of disease.
Published today in Cancer Discovery, results of LOXO-101 against TRK fusion cancer confirm that stage IV patient's tumors had substantially regressed. With four months of treatment, additional CT scans demonstrated almost complete disappearance of the largest tumors.
A paper published today in the Proceedings of the National Academy of Sciences argues against the commonly held "accumulation of mutations" model of oncogenesis in favor of a model that depends on evolutionary pressures acting on populations of cells.
Lancet Oncology reports phase III clinical trial results of necitumumab against stage IV non-small cell lung cancer
Promising clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients.
A University of Colorado Cancer Center study presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 shows decreased sexual activity in women following treatment for gynecologic cancers, down from 6.1-6.8 times per month before treatment to 2.6-4.9 times per month after treatment.
Phase I/II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK+ non-small cell lung cancer (NSCLC), with 58 of 78 ALK+ patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor. Progression-free survival (PFS) in patients previously treated with crizotinib was 13.4 months.
Obesity is a risk factor for breast cancer. A multi-institutional study presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 shows that female breast cancer survivors are able to lose weight through modest lifestyle changes.
Cancer caregivers are stressed, potentially impacting the quality of the care they give. A University of Colorado Cancer Center clinical trial demonstrates how to help.
Study of 11,626 people shows that, all else equal, smokers are 60 percent less likely to vote than nonsmokers.
Analagous to the NCI-60, a new panel of authenticated K9 cancer cell lines presented at AACR 2015 lets veterinary researchers experiment with known cells.
While dietary supplements may be advertised to promote health, a forum at the American Association for Cancer Research (AACR) Annual Meeting 2015 by University of Colorado Cancer Center investigator Tim Byers, MD, MPH, describes research showing that over-the-counter supplements may actually increase cancer risk if taken in excess of the recommended dietary amount.
"It's very simple: tumors from mice that were initially fed silibinin had fewer cancer stem cells, were smaller, had lower metabolisms and showed decreased growth of new blood vessels," says University of Colorado Cancer Center researcher.
At AACR, joint study by NCI and University of Colorado Cancer Center shows TERT is most commonly mutated gene in bladder cancer.
In a major symposium at the American Association for Cancer Research (AACR) Annual Meeting 2015, University of Colorado Cancer Center investigator Tim Byers, MD, MPH, examines research demonstrating the link between cancer, diabetes and cardiovascular disease.
Results presented at AACR 2015 show oncogene recognized in NSCLC in small cell lung cancer, as well, implying that medicines in development for the first may be applicable to second.
New work by the University of Colorado Cancer Center presented at AACR 2015 demonstrates a gene expression model that predicts canine osteosarcoma response to doxorubicin, potentially allowing veterinary oncologists to better choose which drug to use with their patients.
"Tanning beds cause skin cancer. It is time to now more openly announce this causality," says Robert P. Dellavalle, MD, PhD, MSPH, investigator at the CU Cancer Center, in the American Journal of Preventive Medicine.
A University of Colorado Cancer Center study published today in the journal Nature Genetics describes a newly-discovered, heritable genetic cause of acute lymphoblastic leukemia (ALL), namely mutation of the gene ETV6.
University of Colorado Cancer Center study shows that of prostate cancer patients with combination MAP3K7 and CHD1 deletions, about 50 percent will have recurrent prostate cancer, which ultimately leads to death. About 10 percent of all prostate cancers harbor combined MAP3K7-CHD1 deletions.
A University of Colorado Cancer Center study published in the journal Pediatric Blood & Cancer shows that pediatric cancer patients who receive antibiotics within 60 minutes of reporting fever and showing neutropenia (low neutrophil count), go on to have decreased intensive care needs and lower mortality compared with patients who receive antibiotics outside the 60-minute window.
Clinical trials are underway of anti-androgen drugs against high-androgen triple-negative breast cancers, and new work from the University of Colorado Cancer Center shows the threshold for benefit from anti-androgen therapies may be much lower than previously thought: even breast cancers with few androgen receptors benefit from anti-androgen therapy.
University of Colorado Cancer Center study published in the journal SCIENCE shows that mRNA levels for the gene TERT predict patient outcomes in bladder cancer, helping doctors and researchers pinpoint most aggressive forms of the disease and choose appropriate treatments.
45 percent of younger patients report moderate-to-high distress, whereas only 18 percent of older patients report similarly elevated levels.
"Identification of alterations common to adult tumors, in our case upregulation of PIK3R3 and loss of PTEN, could potentially allow us to adapt therapeutic strategies for adult cancers to treat Ewing Sarcoma," says Paul Jedlicka, MD, PhD, investigator at the University of Colorado Cancer Center.
“Increasingly physicians are being presented with health economic analyses in mainstream medical journals as a means of potentially influencing their prescribing. However, it is only when you understand the multiple assumptions behind these calculations that you can see that they are by no means absolute truths,” says D. Ross Camidge, MD, PhD, investigator at the University of Colorado Cancer Center.
A University of Colorado Cancer Center study published in the British Medical Journal: Tobacco Control shows that of the top 100 universities as ranked by U.S. News and World Report, 11 allow tobacco sales and 13 allow e-cigarette sales on “campus cash” debit cards that are commonly prepaid by parents.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right